secwatch.observer — SEC 8-K summary
======================================

Issuer:     RHYTHM PHARMACEUTICALS, INC. (RYTM)
CIK:        0001649904
Form:       8-K
Filed at:   2026-06-15T20:07:28+00:00
Accession:  0001628280-26-043170
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Rhythm posts positive PWS Phase 2 data; MC4R agonist results at ENDO 2026
-------------------------------------------------------------------------

- Interim Phase 2 PWS: 17 patients; mean BMI -3.06% at 6 months; 8/10 with moderate-severe hyperphagia improved ≥7 on HQ-CT.
- Setmelanotide in acquired HO: -18.9% mean BMI reduction after up to 2.5 years (n=11).
- Oral bivamelagon in HO: -16.6% BMI at 1 year for 600 mg dose (n=7).
- Real-world BBS: 62% of adults achieved ≥10% body weight loss at 12 months (n=286); reduced outpatient visits (p<0.05).
- Company plans Phase 3 development in PWS based on data.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649904/000162828026043170/0001628280-26-043170-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649904/000162828026043170/rytm-20260613.htm
  HTML page:      https://secwatch.observer/filing/0001628280-26-043170

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer